{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:39:30Z","timestamp":1785469170182,"version":"3.56.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.seizure.2022.03.020","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T01:56:43Z","timestamp":1648605403000},"page":"8-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["National compliance with UK wide guidelines for usage of valproate in women of childbearing potential"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2904-1442","authenticated-orcid":false,"given":"SH","family":"Eriksson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Tittensor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SM","family":"Sisodiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10282","key":"10.1016\/j.seizure.2022.03.020_bib0001","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(21)00246-4","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.seizure.2022.03.020_bib0002","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa0902014","article-title":"Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy","volume":"362","author":"Glauser","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2022.03.020_bib0003","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","article-title":"Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs","volume":"360","author":"Meador","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2022.03.020_bib0004","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.2013.2270","article-title":"Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism","volume":"309","author":"Christensen","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.seizure.2022.03.020_bib0005","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/referral\/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_en-0.pdf."},{"key":"10.1016\/j.seizure.2022.03.020_bib0006","unstructured":"https:\/\/www.gov.uk\/guidance\/valproate-use-by-women-and-girls."},{"key":"10.1016\/j.seizure.2022.03.020_bib0007","unstructured":"https:\/\/www.epilepsy.org.uk\/involved\/campaigns\/sodium-valproate\/survey."},{"issue":"6","key":"10.1016\/j.seizure.2022.03.020_bib0008","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/ane.13231","article-title":"Valproate risk form-surveying 215 clinicians involving 4775 encounters","volume":"141","author":"Angus-Leppan","year":"2020","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2022.03.020_bib0009","unstructured":"Cumberlege. First Do No Harm: the report of the Independent Medicines and Medical Devices Safety Review. 2020. https:\/\/www.immdsreview.org.uk\/Report.html."},{"issue":"1","key":"10.1016\/j.seizure.2022.03.020_bib0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/epi.12001","article-title":"Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero","volume":"54","author":"Campbell","year":"2013","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.seizure.2022.03.020_bib0011","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1111\/epi.13437","article-title":"EURAP Study Group. Withdrawal of valproic acid treatment during pregnancy and seizure outcome: observations from EURAP","volume":"57","author":"Tomson","year":"2016","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2022.03.020_bib0012","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/WCO.0000000000000668","article-title":"Risks and predictive biomarkers of SUDEP","volume":"32","author":"Ryvlin","year":"2019","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"10.1016\/j.seizure.2022.03.020_bib0013","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1684\/epd.2019.1105","article-title":"Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy","volume":"21","author":"Tomson","year":"2019","journal-title":"Epilept Disord"},{"key":"10.1016\/j.seizure.2022.03.020_bib0014","unstructured":"MBRRACE report \u201cConfidential Enquiries in Maternal Death and Morbidity 2016-18\" (https:\/\/www.npeu.ox.ac.uk\/assets\/downloads\/mbrrace-uk\/reports\/maternal-report-2020\/MBRRACE-UK_Maternal_Report_Dec_2020_v10_ONLINE_VERSION_1404.pdf)."},{"key":"10.1016\/j.seizure.2022.03.020_bib0015","unstructured":"https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/mi-medicines-in-pregnancy-registry\/valproate-use-in-females-aged-0-to-54-in-england-april-2018-to-september-2020."},{"key":"10.1016\/j.seizure.2022.03.020_bib0016","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.seizure.2020.03.015","article-title":"The impact and challenges of the 2018 MHRA statement on the use of sodium valproate in women of childbearing age during the first year of implementation, in a UK epilepsy centre","volume":"79","author":"Davies","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2022.03.020_bib0017","unstructured":"https:\/\/www.nice.org.uk\/guidance\/cg137."},{"key":"10.1016\/j.seizure.2022.03.020_bib0018","unstructured":"Medicines and Healthcare Products Regulatory Agency. Antiepileptic drugs: review of safety of use during pregnancy. 2021 https:\/\/www.gov.uk\/government\/publications\/public-assesment-report-of-antiepilepticdrugs-review-of-safety-of-use-during-pregnancy."},{"key":"10.1016\/j.seizure.2022.03.020_bib0019","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.seizure.2016.09.003","article-title":"Stopping epilepsy treatment in seizure remission: good or bad or both?","volume":"44","author":"Schmidt","year":"2017","journal-title":"Seizure"},{"issue":"7","key":"10.1016\/j.seizure.2022.03.020_bib0020","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/ene.13016","article-title":"Managing anti-epileptic drug treatment in adult patients with intellectual disability: a serious conundrum","volume":"23","author":"Doran","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.seizure.2022.03.020_bib0021","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/ane.13337","article-title":"Valproate prescribing practices for women with intellectual disability across Europe","volume":"143","author":"Watkins","year":"2021","journal-title":"Acta Neurol Scand"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105913112200070X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105913112200070X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:59:20Z","timestamp":1761011960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105913112200070X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":21,"alternative-id":["S105913112200070X"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2022.03.020","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"National compliance with UK wide guidelines for usage of valproate in women of childbearing potential","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2022.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}